Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance atezolizumab + apatinib after salvage chemoradiotherapy for regional lymph node metastases of esophageal squamous cell carcinoma
ChiCTR2600122700Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-Free Survival. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
atezolizumabRivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600122700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122700.